To NASDAQ OMX Copenhagen A/S
Announcement No. 18-10 / Copenhagen, 30 April, 2010
Topotarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.Topotarget.com

Disclosure obligation concerning share capital and voting rights at 30 April
2010

Copenhagen, Denmark - 30 April, 2010 - Topotarget A/S (NASDAQ OMX: TOPO.CO) On
12 April 2010, TopoTarget A/S increased its share capital by 43,030 shares. In
accordance with Executive Order no. 220 of 10 March 2010 concerning Issuers'
Disclosure Obligations, it is hereby notified that on 30 April 2010, TopoTarget
A/S had a share capital of nominal DKK 132,652,050, consisting of 132,652,050
shares each of DKK 1 nominal value. Each share of DKK 1 carries one vote,
corresponding to a total number of voting rights of 132,652,050.




Topotarget A/S

For further information, please contact:

Francois Martelet, CEO: Direct: +45 39 17 94 99; Mobile: +45 31 36 83 41
Anders Vadsholt, CFO: Direct: +45 39 17 83 45; Mobile: +45 28 98 90 55



Background information

About Topotarget

Topotarget (NASDAQ OMX: TOPO) is an international biotech company headquartered
in Denmark, dedicated to improve cancer therapies. Topotarget currently
focuses, in collaboration with Spectrum Pharmaceuticals, Inc., on the
development in pivotal studies of its lead drug candidate, belinostat, which
has shown proof-of-concept as monotherapy in treating haematological
malignancies and positive results in solid tumours. Belinostat can be used in
combination with full doses of chemotherapy, and is currently in a pivotal
trial within PTCL (peripheral T-cell lymphoma). Topotarget's key cancer drugs
target HDAC, NAD+, mTOR, Fas ligand and topoisomerase II. The company's first
marketed product, Savene®/Totect®, was approved by EMEA in 2006 and the FDA in
2007, and is marketed by Topotarget's own sales force in the US. For more
information, please refer to www.Topotarget.com.

announcement no 18-10 disclosure obligation concerning share capital and voting rights.pdf